Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1985 1
1987 1
1990 3
1993 1
1994 2
2010 1
2014 1
2021 1
2022 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
A comparative study of cholecalciferol, dihydrotachysterol and alfacalcidol in the treatment of elderly patients with hypocalcaemia.
Hamdy RC, Coles JA, Downey LJ. Hamdy RC, et al. Age Ageing. 1987 May;16(3):178-80. doi: 10.1093/ageing/16.3.178. Age Ageing. 1987. PMID: 3037863 Clinical Trial.
Fifty elderly patients with hypocalcaemia were randomly treated for 8 weeks with either oral dihydrotachysterol, parenteral cholecalciferol or oral alfacalcidol. All three treatments were successful in normalizing the serum calcium levels in most patients within 2 weeks. . …
Fifty elderly patients with hypocalcaemia were randomly treated for 8 weeks with either oral dihydrotachysterol, parenteral cholecalc …
Differences in the bioavailability of dihydrotachysterol preparations.
Koytchev R, Alken RG, Vagaday M, Kunter U, Kirkov V. Koytchev R, et al. Eur J Clin Pharmacol. 1994;47(1):81-4. doi: 10.1007/BF00193484. Eur J Clin Pharmacol. 1994. PMID: 7988630 Clinical Trial.
The bioavailability of four preparations containing dihydrotachysterol (DHT2) was tested in two separate trials with administration of single, oral doses of 1 mg per individual. ...
The bioavailability of four preparations containing dihydrotachysterol (DHT2) was tested in two separate trials with administration o …
A prospective, double-blind study of growth failure in children with chronic renal insufficiency and the effectiveness of treatment with calcitriol versus dihydrotachysterol. The Growth Failure in Children with Renal Diseases Investigators.
Chan JC, McEnery PT, Chinchilli VM, Abitbol CL, Boineau FG, Friedman AL, Lum GM, Roy S 3rd, Ruley EJ, Strife CF. Chan JC, et al. J Pediatr. 1994 Apr;124(4):520-8. doi: 10.1016/s0022-3476(05)83128-2. J Pediatr. 1994. PMID: 8151464 Clinical Trial.
There was no significant difference between calcitriol and dihydrotachysterol in promoting linear growth or causing hypercalcemia in children with chronic renal insufficiency. Dihydrotachysterol, the less costly agent, can be used with equal efficacy....
There was no significant difference between calcitriol and dihydrotachysterol in promoting linear growth or causing hypercalcemia in …
Interventions for bone disease in children with chronic kidney disease.
Geary DF, Hodson EM, Craig JC. Geary DF, et al. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD008327. doi: 10.1002/14651858.CD008327. Cochrane Database Syst Rev. 2010. Update in: Cochrane Database Syst Rev. 2015 Nov 12;(11):CD008327. doi: 10.1002/14651858.CD008327.pub2 PMID: 20091666 Updated. Review.
No significant differences were detected in growth rates, bone histology or biochemical parameters between calcitriol and either dihydrotachysterol or ergocalciferol (2 RCTs). Though fewer episodes of hypercalcaemia were reported with sevelamer, no significant differences …
No significant differences were detected in growth rates, bone histology or biochemical parameters between calcitriol and either dihydrot …
Suppression of secondary hyperparathyroidism in children with chronic renal failure by high dose phosphate binders: calcium carbonate versus aluminium hydroxide.
Mak RH, Turner C, Thompson T, Powell H, Haycock GB, Chantler C. Mak RH, et al. Br Med J (Clin Res Ed). 1985 Sep 7;291(6496):623-7. doi: 10.1136/bmj.291.6496.623. Br Med J (Clin Res Ed). 1985. PMID: 3928054 Free PMC article. Clinical Trial.
The patients were randomised to receive either aluminium hydroxide or calcium carbonate by mouth for six months and then crossed over to the other medication. Vitamin D (dihydrotachysterol) dosage was unchanged. Serum parathyroid hormone concentrations were reduced to with …
The patients were randomised to receive either aluminium hydroxide or calcium carbonate by mouth for six months and then crossed over to the …
Descriptions of the participating centers and patient population in the Growth Failure in Children with Renal Diseases Study.
Chan JC, Boineau FG, Ruley EJ, Lum GM, Weiss RA, Waldo FB, Pomrantz A, Hellerstein S, Fine RN. Chan JC, et al. J Pediatr. 1990 Feb;116(2):S24-7. doi: 10.1016/s0022-3476(05)82920-8. J Pediatr. 1990. PMID: 2405131 Clinical Trial.
The study design of randomization to two treatment arms (1,25-dihydroxyvitamin D vs dihydrotachysterol) requires a total of 108 patients with a minimum of 6 months of treatment to test the long-term effectiveness and safety of 1,25-dihydroxyvitamin D, an essential part of …
The study design of randomization to two treatment arms (1,25-dihydroxyvitamin D vs dihydrotachysterol) requires a total of 108 patie …
Linear growth and anthropometric and nutritional measurements in children with mild to moderate renal insufficiency: a report of the Growth Failure in Children with Renal Diseases Study.
Abitbol CL, Warady BA, Massie MD, Baluarte HJ, Fleischman LE, Geary DF, Kaiser BA, McEnery PT, Chan JC. Abitbol CL, et al. J Pediatr. 1990 Feb;116(2):S46-54. doi: 10.1016/s0022-3476(05)82925-7. J Pediatr. 1990. PMID: 2405136 Free article. Clinical Trial.
As a multicenter, controlled clinical trial designed to study the relative efficacy of 1,25-dihydroxyvitamin D3 and dihydrotachysterol in the treatment of renal osteodystrophy, no prior vitamin D exposure and a creatinine clearance of 25 to 75 ml/min/1.73 m2 were criteria …
As a multicenter, controlled clinical trial designed to study the relative efficacy of 1,25-dihydroxyvitamin D3 and dihydrotachysterol …
12 results